NewAmsterdam Pharma (NASDAQ:NAMSW) Short Interest Update

NewAmsterdam Pharma (NASDAQ:NAMSW) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 13,300 shares, a growth of 66.3% from the March 31st total of 8,000 shares. Based on an average daily volume of 12,500 shares, the short-interest ratio is currently 1.1 days.

Institutional Inflows and Outflows

An institutional investor recently raised its position in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC boosted its stake in shares of NewAmsterdam Pharma (NASDAQ:NAMSW) by 270.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 137,000 shares of the company’s stock after purchasing an additional 100,000 shares during the period. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $260,000 at the end of the most recent reporting period.

NewAmsterdam Pharma Stock Up 24.3 %

Shares of NewAmsterdam Pharma stock traded up $2.36 on Monday, reaching $12.09. The stock had a trading volume of 93 shares, compared to its average volume of 16,534. The company has a 50 day moving average price of $10.49 and a 200 day moving average price of $6.43. NewAmsterdam Pharma has a 1 year low of $0.99 and a 1 year high of $14.67.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.